Drug interactions
Lorlatinib + Vemurafenib
Severity: Moderate
Lorlatinib and Vemurafenib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Lorlatinib may reduce vemurafenib exposure and efficacy. Vemurafenib is itself a CYP3A4 inducer, so lorlatinib exposure may also be reduced.
What this interaction means in plain words
Lorlatinib and Vemurafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Lorlatinib belongs to Oncology; Vemurafenib belongs to Oncology.
Why it happens
Lorlatinib induces CYP3A4, increasing metabolism of vemurafenib, a CYP3A4 substrate.
What to do
Monitor tumor response. Avoid the combination if alternatives exist.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lorlatinib and Vemurafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Lorlatinib
- Amobarbital + Lorlatinib Contraindicated
- Apalutamide + Lorlatinib Contraindicated
- Butabarbital + Lorlatinib Contraindicated
- Carbamazepine + Lorlatinib Contraindicated
- Enzalutamide + Lorlatinib Contraindicated
- Fosphenytoin + Lorlatinib Contraindicated
Other interactions of Vemurafenib
Frequently asked questions
Can I take Lorlatinib with Vemurafenib?
MediHelp rates the interaction as moderate. Lorlatinib and Vemurafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Lorlatinib may reduce vemurafenib exposure and efficacy. Vemurafenib is itself a CYP3A4 inducer, so lorlatinib exposure may also be reduced.
How serious is the interaction between Lorlatinib and Vemurafenib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor tumor response. Avoid the combination if alternatives exist.
What other medicines interact with Lorlatinib?
MediHelp also lists interactions of Lorlatinib with, for example, Amobarbital, Apalutamide, Butabarbital. The full list is on the Lorlatinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
